Form 8-K

8-K — SBC Medical Group Holdings Inc

Accession: 0001193125-26-222720

Filed: 2026-05-14

Period: 2026-05-14

CIK: 0001930313

SIC: 8011 (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — sbc-20260514.htm (Primary)

EX-99.1 (sbc-ex99_1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: sbc-20260514.htm · Sequence: 1

8-K

false00019303130001930313sbc:CommonStock0.0001ParValuePerShareMember2026-05-142026-05-1400019303132026-05-142026-05-140001930313sbc:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember2026-05-142026-05-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 14, 2026

SBC Medical Group Holdings Incorporated

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-41462

88-1192288

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

200 Spectrum Center Dr., STE 300

Irvine, California

92618

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 949 593-0250

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

SBC

The Nasdaq Stock Market LLC

Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share

SBCWW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 14, 2026, SBC Medical Group Holdings Incorporated (the “Company”), issued a press release announcing its results for the quarter ended March 31, 2026. The press release is attached as Exhibit 99.1 and is incorporated herein by reference.

The information furnished under Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated by specific reference in any such filing.

Item 7.01 Regulation FD Disclosure.

Additionally, on May 14, 2026, the Company posted an investor presentation to its website, entitled “1Q 2026 Investor Presentation,” which provides an overview of its business (https://ir.sbc-holdings.com/presentations/). From time to time, the Company uses its website (https://ir.sbc-holdings.com/) to distribute company information and makes available free of charge a variety of information for investors, including its filings with the Securities and Exchange Commission (“SEC”), as soon as reasonably practicable after electronically filing that material with, or furnishing it, to the SEC. The information that the Company posts on its website may be deemed material. Accordingly, investors should monitor the Company’s website, in addition to following its press releases, filings with the SEC, and public conference calls and webcasts. Investors may opt in to automatically receive email alerts and other information about the Company when enrolling their email address by visiting the “Email Alerts” section under the “Resources” tab on its website. The Company does not incorporate the information contained on, or accessible through, its website or related social media channels into this Current Report on Form 8-K.

The information furnished under this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing under the Securities Act, or the Exchange Act, except as otherwise expressly stated by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

99.1

Press Release, dated May 14, 2026, entitled “SBC Medical Group Holdings Announces First Quarter 2026 Financial Results”

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SBC Medical Group Holdings Incorporated

Date:

May 14, 2026

By:

/s/ Yuya Yoshida

Name:

Title:

Yuya Yoshida

Chief Financial Officer and Chief Operating Officer

EX-99.1

Filename: sbc-ex99_1.htm · Sequence: 2

EX-99.1

Exhibit 99.1

SBC Medical Group Holdings Announces First Quarter 2026 Financial Results

IRVINE, Calif. --SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization providing management support across a wide range of healthcare fields, today announced its financial results for the three months ended March 31, 2026.

First Quarter 2026 Highlights

•

Total revenues were $43 million, representing a 9% year-over-year decrease.

•

Net income attributable to SBC Medical Group Holdings Incorporated was $11 million, representing a 47% year-over-year decrease. Net income margin was 26% for the first quarter of 2026, representing a year-over-year decrease of 19 percentage points.

•

Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.11 for the three months ended March 31, 2026, representing a 48% year-over-year decrease.

•

EBITDA1, which is calculated by adding depreciation and amortization expense to income from operations was $18 million, representing a 26% year-over-year decrease. EBITDA margin1 was 43% for the first quarter of 2026, representing a year-over-year decrease of 10 percentage points.

•

Return on equity2, which is defined as net income attributable to the Company divided by the average shareholders' equity as of March 31, 2026, was 18% representing a year-over-year decrease of 23 percentage points.

•

Number of franchise locations3 was 284 as of March 31, 2026, representing an increase of 33 locations from March 31, 2025.

•

Number of customers4 in the last twelve months ended March 31, 2026, was 6.76 million, representing a 10% year-over-year increase.

•

Repeat rate for customers5 who visited franchisee’s clinics twice or more was 72%.

Yoshiyuki Aikawa, Chairman and Chief Executive Officer of SBC Medical, said, “For the first quarter of fiscal year 2026, SBC Medical reported revenue of $43 million, representing a 9% year-over-year decline. This decrease was primarily attributable to a strategic structural reform implemented in April 2025, involving a revision of the franchise fee structure. Excluding this structural change, the performance of our core business remained solid. In terms of profitability, our net income margin was 26%, and our EBITDA margin remained at a high level of 43%.

Looking ahead, we will continue to promote our multi-brand strategy in the aesthetic dermatology field, expand our non-aesthetic medical business, and strengthen our operational foundation in overseas markets. In addition, we will pursue opportunities in the longevity market and further enhance our services through the utilization of AI, with the goal of building a sustainable and continuously growing healthcare platform.”

1 EBITDA and EBITDA margin are non-GAAP financial measures. For more information on non-GAAP financial measures, please see the section “Use of Non-GAAP Financial Measures” and the table captioned “Unaudited Reconciliations of GAAP and Non-GAAP Results.”

2 Return on equity is presented on an annualized basis.

3 The figure includes locations of the franchising of SBC brand clinics, Rize Clinic, Gorilla Clinic, AHH Clinic, JUN CLINIC, OrangeTwist.

4 The customer count includes customers of SBC brand clinics, Rize Clinic, Gorilla Clinic, AHH Clinic, and JUN CLINIC. The applicable periods are from April 1, 2025 to March 31, 2026.

5 The figures include franchised SBC brand clinics, Rize Clinic, Gorilla Clinic, AHH Clinic, and JUN Clinic, excluding free counseling. The percentages represent customers who visited our franchisees' clinics twice or more. Please note that the unique counts and repeat rates for AHH clinics and JUN clinics are estimated based on the ratios of SBC brand clinics, Rize clinics, and Gorilla clinics.

Conference Call

The Company will hold a conference call on Thursday, May 14, 2026, at 8:30 a.m. Eastern Time (or Thursday, May 14, 2026, at 9:30 p.m. Japan Time) to discuss the financial results for the first quarter ended March 31, 2026. A question‑and‑answer session with analysts and investors will follow the prepared remarks.

Please register in advance of the conference using the link provided below.

https://zoom.us/webinar/register/WN_6RZgrwsUREiRpAmBBGTikA

It will automatically direct you to the registration page of “ 1Q 2026 Earning Call ”. Please follow the steps to enter your registration details, then click “Submit.”. Upon registration, you will be able to access the dedicated Conference Call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well as past investor relations materials.

Additionally, the earnings release, accompanying slides, and an archived webcast of this conference call will be available at the Company’s Investor Relations website at https://ir.sbc-holdings.com/

About SBC Medical

SBC Medical Group Holdings Incorporated is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.

For more information, visit https://sbc-holdings.com/en

For more insights and updates from SBC Medical, follow us on LinkedIn.

Use of Non-GAAP Financial Measures

The Company uses non-GAAP measures, such as EBITDA and EBITDA margin, in evaluating its operating results and for financial and operational decision-making purposes. The Company believes that the non-GAAP financial measures help identify underlying trends in its business. The Company believes that the non-GAAP financial measures provide useful information about the Company’s results of operations, enhance the overall understanding of the Company’s past performance and future prospects and allow for greater visibility with respect to key metrics used by the Company’s management in its financial and operational decision-making.

The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools, and when assessing the Company’s operating performance, cash flows or liquidity, investors should not consider them in isolation, or as a substitute for net income (loss), net income margin, cash flows provided by operating activities, or other consolidated statements of operations and cash flows data prepared in accordance with U.S. GAAP.

The Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating the Company’s performance.

For more information on the non-GAAP financial measures, please see the table captioned “Unaudited Reconciliations of GAAP and Non-GAAP Results.”

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s financial performance; growth in revenue and earnings; business prospects and opportunities; and capital deployment plans and liquidity. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

SBC MEDICAL GROUP HOLDINGS INCORPORATED

UNAUDITED CONSOLIDATED BALANCE SHEETS

March 31,

2026

December 31,

2025

ASSETS

Current assets:

Cash and cash equivalents

167,305,095

163,773,838

Accounts receivable

2,980,193

2,388,021

Accounts receivable – related parties

33,784,532

27,511,730

Inventories

2,323,880

2,792,617

Short-term investments – related parties

313,865

319,193

Finance lease receivables, current – related parties

13,326,150

12,832,355

Income tax recoverable

1,173,913

1,175,510

Customer loans receivable, current

6,659,837

8,705,999

Prepaid expenses and other current assets

10,912,717

11,724,852

Total current assets

238,780,182

231,224,115

Non-current assets:

Property and equipment, net

7,287,369

7,539,392

Intangible assets, net

47,152,285

47,742,888

Long-term investments, net

1,198,583

1,299,366

Equity method investments

20,312,642

Goodwill, net

15,398,049

15,432,061

Finance lease receivables, non-current – related parties

12,548,800

13,746,513

Operating lease right-of-use assets

11,084,198

8,366,569

Finance lease right-of-use assets

392,118

450,874

Deferred tax assets

4,975,629

4,014,294

Customer loans receivable, non-current

3,454,969

4,824,977

Long-term prepayments

705,430

393,270

Long-term investments in MCs – related parties

17,539,564

17,837,293

Other assets

7,189,758

7,263,692

Total non-current assets

149,239,394

149,223,831

Total assets

388,019,576

380,447,946

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

19,168,072

16,988,384

Accounts payable – related parties

527,624

651,463

Bank and other borrowings, current

8,987,118

9,099,046

Advances from customers

1,011,249

1,415,762

Advances from customers – related parties

4,217,057

5,357,221

Income tax payable

8,450,440

8,821,853

Operating lease liabilities, current

5,521,371

4,416,960

Finance lease liabilities, current

118,297

132,946

Accrued liabilities and other current liabilities

11,896,371

11,544,695

Due to related party

2,670,016

2,692,673

Total current liabilities

62,567,615

61,121,003

SBC MEDICAL GROUP HOLDINGS INCORPORATED

UNAUDITED CONSOLIDATED BALANCE SHEETS — (Continued)

March 31,

2026

December 31,

2025

Non-current liabilities:

Bank and other borrowings, non-current

31,447,900

33,734,438

Deferred tax liabilities

16,215,816

16,374,832

Operating lease liabilities, non-current

5,731,514

4,136,257

Finance lease liabilities, non-current

93,600

116,527

Other liabilities

1,578,954

1,660,183

Total non-current liabilities

55,067,784

56,022,237

Total liabilities

117,635,399

117,143,240

Commitments and contingencies (Note 19)

Stockholders’ equity:

Preferred stock ($0.0001 par value, 20,000,000 shares authorized; no shares issued and outstanding as of March 31, 2026 and December 31, 2025)

—

Common stock ($0.0001 par value, 400,000,000 shares authorized, 103,881,251 shares issued, and 102,576,943 shares outstanding as of March 31, 2026 and December 31, 2025)

10,388

Additional paid-in capital

72,867,424

Treasury stock (at cost, 1,304,308 shares as of March 31, 2026 and December 31, 2025)

(7,749,997

)

(7,749,997

)

Retained earnings

251,756,691

240,448,620

Accumulated other comprehensive loss

(61,541,134

)

(57,294,239

)

Total SBC Medical Group Holdings Incorporated stockholders’ equity

255,343,372

248,282,196

Non-controlling interests

15,040,805

15,022,510

Total stockholders’ equity

270,384,177

263,304,706

Total liabilities and stockholders’ equity

388,019,576

380,447,946

SBC MEDICAL GROUP HOLDINGS INCORPORATED

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

For the Three Months

Ended March 31,

2026

2025

Revenues, net – related parties

37,955,060

45,257,145

Revenues, net

5,105,502

2,071,556

Total revenues, net

43,060,562

47,328,701

Cost of revenues (including cost of revenues from related parties of $124,389 and $3,456,928 for the three months ended March 31, 2026 and 2025, respectively)

12,713,828

9,595,617

Gross profit

30,346,734

37,733,084

Operating expenses:

Selling, general and administrative expenses (including selling, general and administrative expenses from related parties of $343,393 and nil for the three months ended March 31, 2026 and 2025, respectively)

12,626,719

13,531,010

Total operating expenses

12,626,719

13,531,010

Income from operations

17,720,015

24,202,074

Other income (expenses):

Interest income

121,369

55,333

Interest expense

(114,806

)

(6,207

)

Foreign currency exchange gain (loss), net

861,678

(1,058,526

)

Other income

491,564

151,328

Other expenses

(223,209

)

(638,733

)

Gain on redemption of life insurance policies

—

8,746,138

Total other income

1,136,596

7,249,333

Income before income taxes

18,856,611

31,451,407

Income tax expense

7,527,591

9,959,457

Net income

11,329,020

21,491,950

Less: net income (loss) attributable to non-controlling interests

20,949

(10,496

)

Net income attributable to SBC Medical Group Holdings Incorporated

11,308,071

21,502,446

Other comprehensive income (loss):

Foreign currency translation adjustment

(4,249,549

)

9,808,327

Total comprehensive income

7,079,471

31,300,277

Less: comprehensive income (loss) attributable to non-controlling interests

18,295

(36,832

)

Comprehensive income attributable to SBC Medical Group Holdings Incorporated

7,061,176

31,337,109

Net income per share attributable to SBC Medical Group Holdings Incorporated

Basic and diluted

0.11

0.21

Weighted average shares outstanding

Basic and diluted

102,576,943

103,276,637

SBC MEDICAL GROUP HOLDINGS INCORPORATED

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Three Months

Ended March 31,

2026

2025

CASH FLOWS FROM OPERATING ACTIVITIES

Net income

11,329,020

21,491,950

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization expense

670,434

628,304

Non-cash lease expense

1,420,824

985,184

Provision for (reversal of) credit losses

(31,353

)

25,102

Fair value change of long-term investments

80,301

140,581

Gain on redemption of life insurance policies

—

(8,746,138

)

Gain on disposal of property and equipment

—

(12,375

)

Deferred income taxes

(1,086,473

)

7,016,227

Changes in operating assets and liabilities:

Accounts receivable

(627,606

)

(147,925

)

Accounts receivable - related parties

(6,821,339

)

(295,505

)

Inventories

442,643

(124,279

)

Finance lease receivables - related parties

264,252

(2,779,253

)

Customer loans receivable

3,270,347

4,501,760

Prepaid expenses and other current assets

629,253

(3,150,243

)

Long-term prepayments

31,592

98,164

Other assets

(66,265

)

318,351

Accounts payable

2,484,437

3,235,017

Accounts payable - related parties

(114,689

)

441,481

Notes payables - related parties

—

(548,077

)

Advances from customers

(386,997

)

(328,791

)

Advances from customers - related parties

(1,066,776

)

(2,114,829

)

Income tax payable

(245,955

)

(17,635,239

)

Operating lease liabilities

(1,424,716

)

(1,036,605

)

Accrued liabilities and other current liabilities

543,412

63,764

Other liabilities

(62,408

)

(98,005

)

NET CASH PROVIDED BY OPERATING ACTIVITIES

9,231,938

1,928,621

CASH FLOWS FROM INVESTING ACTIVITIES

Purchase of property and equipment

(124,995

)

(253,725

)

Prepayments for property and equipment

(423,870

)

(501,253

)

Purchase of long-term investments

—

(635,145

)

Long-term loans to others

—

(12,783

)

Repayments from related parties

—

70,000

Repayments from others

20,840

30,680

Proceeds from disposal of property and equipment

—

323,419

NET CASH USED IN INVESTING ACTIVITIES

(528,025

)

(978,807

)

CASH FLOWS FROM FINANCING ACTIVITIES

Borrowings from related parties

—

15,000

Repayments of bank and other borrowings

(1,782,479

)

(55,873

)

Repayments of finance lease liabilities

(37,278

)

(223,454

)

Repayments to related parties

(22,657

)

(16,053

)

NET CASH USED IN FINANCING ACTIVITIES

(1,842,414

)

(280,380

)

Effect of exchange rate changes

(3,330,242

)

6,342,297

NET CHANGE IN CASH AND CASH EQUIVALENTS

3,531,257

7,011,731

CASH AND CASH EQUIVALENTS AS OF THE BEGINNING OF THE PERIOD

163,773,838

125,044,092

CASH AND CASH EQUIVALENTS AS OF THE END OF THE PERIOD

167,305,095

132,055,823

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

Cash paid for interest expense

114,806

6,207

Cash paid for income taxes, net

8,848,074

20,577,290

SBC MEDICAL GROUP HOLDINGS INCORPORATED

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS — (Continued)

For the Three Months

Ended March 31,

2026

2025

NON-CASH INVESTING AND FINANCING ACTIVITIES

Property and equipment transferred from long-term prepayments

68,691

125,287

Operating lease right-of-use assets obtained in exchange for operating lease liabilities

19,664

102,599

Finance lease right-of-use assets obtained in exchange for finance lease liabilities

—

581,129

Remeasurement of operating lease liabilities and right-of-use assets due to lease modifications

4,260,931

358,358

Payables to related parties in connection with loan services provided

—

1,922,224

Issuance of common stock as incentive shares

—

Redemption proceeds receivable on life insurance policies

—

17,735,717

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

SBC MEDICAL GROUP HOLDINGS INCORPORATED

Unaudited Reconciliations of GAAP and Non-GAAP Results

For the Three Months Ended

March 31,

2026

2025

Total Revenues, net

43,060,562

47,328,701

Net income attributable to SBC Medical Group Holdings Incorporated

11,308,071

21,502,446

Net income margin

Income from operations

17,720,015

24,202,074

Depreciation and amortization expense

670,434

628,304

EBITDA

18,390,449

24,830,378

EBITDA margin

Net income margin is defined as net income attributable to SBC Medical Group Holdings Incorporated divided by total revenues, net. EBITDA is calculated by adding depreciation and amortization expense to income from operations. EBITDA margin is defined as EBITDA divided by total revenues, net.

Contacts

SBC Medical Group Holdings Incorporated

Hikaru Fukui / Head of IR Department E-mail: ir@sbc-holdings.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 5

v3.26.1

Document And Entity Information

May 14, 2026

Document Information [Line Items]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 14, 2026

Entity Registrant Name

SBC Medical Group Holdings Incorporated

Entity Central Index Key

0001930313

Entity Emerging Growth Company

true

Entity File Number

001-41462

Entity Incorporation, State or Country Code

Entity Tax Identification Number

88-1192288

Entity Address, Address Line One

200 Spectrum Center Dr., STE 300

Entity Address, City or Town

Irvine

Entity Address, State or Province

Entity Address, Postal Zip Code

92618

City Area Code

949

Local Phone Number

593-0250

Entity Information, Former Legal or Registered Name

Not Applicable

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Ex Transition Period

false

Common Stock, $0.0001 par value per share

Document Information [Line Items]

Title of 12(b) Security

Common Stock, $0.0001 par value per share

Trading Symbol

SBC

Security Exchange Name

NASDAQ

Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share

Document Information [Line Items]

Title of 12(b) Security

Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share

Trading Symbol

SBCWW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_DocumentInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

Former Legal or Registered Name of an entity

+ References

No definition available.

+ Details

Name:

dei_EntityInformationFormerLegalOrRegisteredName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=sbc_CommonStock0.0001ParValuePerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=sbc_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: